Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 2146

1.

Effects of testosterone and 17β-estradiol on osteogenic and adipogenic differentiation capacity of human bone-derived mesenchymal stromal cells of postmenopausal women.

Glenske K, Schuler G, Arnhold S, Elashry MI, Wagner AS, Barbeck M, Neumann E, Müller-Ladner U, Schnettler R, Wenisch S.

Bone Rep. 2019 Oct 21;11:100226. doi: 10.1016/j.bonr.2019.100226. eCollection 2019 Dec.

PMID:
31709277
2.

Is omalizumab safe and effective in oncological patients?

Navarro-Triviño FJ, Mérida-Fernández C, Linares-Gonzalez L, Ruiz-Villaverde R.

Dermatol Ther. 2019 Oct 16:e13115. doi: 10.1111/dth.13115. [Epub ahead of print]

PMID:
31646716
3.

Aromatase Inhibitors.

LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-.
2017 Jul 27.

4.

Anastrozole.

LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-.
2017 Jul 25.

5.

Validation of the OncoMasTR Risk Score in Estrogen Receptor-Positive/HER2-Negative Patients: a TransATAC study.

Buus R, Sestak I, Barron S, Loughman T, Fender B, Ruiz CL, Dynoodt P, Wang CA, O'Leary D, Gallagher WM, Dowsett M, Cuzick J.

Clin Cancer Res. 2019 Oct 22. pii: clincanres.0712.2019. doi: 10.1158/1078-0432.CCR-19-0712. [Epub ahead of print]

PMID:
31641007
6.

A systematic review and meta-analysis of clinical trials implementing aromatase inhibitors to treat male infertility.

Del Giudice F, Busetto GM, De Berardinis E, Sperduti I, Ferro M, Maggi M, Gross MS, Sciarra A, Eisenberg ML.

Asian J Androl. 2019 Oct 15. doi: 10.4103/aja.aja_101_19. [Epub ahead of print]

PMID:
31621654
7.

Potent cell cycle inhibition and upregulation of immune response with abemaciclib and anastrozole in neoMONARCH, Phase 2 neoadjuvant study in HR+/HER2- breast cancer.

Hurvitz SA, Martín M, Press MF, Chan D, Fernandez-Abad M, Petru E, Rostorfer R, Guarneri V, Huang CS, Barriga S, Wijayawardana SR, Brahmachary M, Ebert PJ, Hossain A, Liu J, Abel A, Aggarwal A, Jansen VM, Slamon DJ.

Clin Cancer Res. 2019 Oct 15. pii: clincanres.1425.2019. doi: 10.1158/1078-0432.CCR-19-1425. [Epub ahead of print]

PMID:
31615937
8.

Cancer Genes Mutations in Benign Metastasizing Leiomyoma: A Case Report.

Nguyen TC, Drew PA, Dang LH, Yuan C.

Cureus. 2019 Jul 16;11(7):e5154. doi: 10.7759/cureus.5154.

9.

Medication Use for the Risk Reduction of Primary Breast Cancer in Women: A Systematic Review for the U.S. Preventive Services Task Force [Internet].

Nelson HD, Fu R, Zakher B, McDonagh M, Pappas M, Stillman L.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2019 Sep.

10.

Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.

Giuliano M, Schettini F, Rognoni C, Milani M, Jerusalem G, Bachelot T, De Laurentiis M, Thomas G, De Placido P, Arpino G, De Placido S, Cristofanilli M, Giordano A, Puglisi F, Pistilli B, Prat A, Del Mastro L, Venturini S, Generali D.

Lancet Oncol. 2019 Oct;20(10):1360-1369. doi: 10.1016/S1470-2045(19)30420-6. Epub 2019 Sep 4.

PMID:
31494037
11.

Use of Endocrine Therapy for Breast Cancer Risk Reduction: ASCO Clinical Practice Guideline Update.

Visvanathan K, Fabian CJ, Bantug E, Brewster AM, Davidson NE, DeCensi A, Floyd JD, Garber JE, Hofstatter EW, Khan SA, Katapodi MC, Pruthi S, Raab R, Runowicz CD, Somerfield MR.

J Clin Oncol. 2019 Sep 3:JCO1901472. doi: 10.1200/JCO.19.01472. [Epub ahead of print]

PMID:
31479306
12.

Medication Use for the Risk Reduction of Primary Breast Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.

Nelson HD, Fu R, Zakher B, Pappas M, McDonagh M.

JAMA. 2019 Sep 3;322(9):868-886. doi: 10.1001/jama.2019.5780.

PMID:
31479143
13.

A novel GC-MS methodology to evaluate aromatase activity in human placental microsomes: a comparative study with the standard radiometric assay.

Augusto TV, Cunha SC, Amaral C, Fernandes JO, da Silva ET, Roleira FFM, Teixeira N, Correia-da-Silva G.

Anal Bioanal Chem. 2019 Oct;411(26):7005-7013. doi: 10.1007/s00216-019-02076-7. Epub 2019 Aug 22.

PMID:
31440781
14.

Effects of honey supplementation on safety profiles among postmenopausal breast cancer patients.

Zakaria Z, Zainal Abidin ZF, Gan SH, Wan Abdul Hamid WZ, Mohamed M.

J Taibah Univ Med Sci. 2018 Aug 25;13(6):535-540. doi: 10.1016/j.jtumed.2018.04.013. eCollection 2018 Dec.

15.

Efficacy of denosumab for restoring normal bone mineral density in women receiving adjuvant aromatase inhibitors for early breast cancer.

Sakaguchi K, Ono H, Nakatsukasa K, Ishikawa T, Hasegawa Y, Takahashi M, Niikura N, Koizumi K, Sakurai T, Shigematsu H, Takahashi S, Taira S, Suzuki M, Narui K, Miura D, Yamada K, Yoshimura M, Shioya H, Konishi E, Isao Y, Imai K, Fujikawa K, Taguchi T; Collaborative Study Group of Scientific Research of the Japanese Breast Cancer Society.

Medicine (Baltimore). 2019 Aug;98(32):e16770. doi: 10.1097/MD.0000000000016770.

16.

Role of testosterone and androgen receptor in periodontal disease progression in female rats.

Steffens JP, Valenga HM, Santana LCL, Albaricci MCDC, Kantarci A, Spolidorio LC.

J Periodontol. 2019 Aug 7. doi: 10.1002/JPER.19-0099. [Epub ahead of print]

PMID:
31389012
17.

Long-Term Survival and Complete Response to Anastrozole in Breast Cancer Patient With Cutaneous Metastases Only.

Sedloev T, Vlahova A, Usheva S, Vasileva-Slaveva M, Spiridonova T, Spirdonov J.

Anticancer Res. 2019 Aug;39(8):4393-4398. doi: 10.21873/anticanres.13609.

PMID:
31366535
18.

PARAGON (ANZGOG-0903): a phase 2 study of anastrozole in asymptomatic patients with estrogen and progesterone receptor-positive recurrent ovarian cancer and CA125 progression.

Kok PS, Beale P, O'Connell RL, Grant P, Bonaventura T, Scurry J, Antill Y, Goh J, Sjoquist K, DeFazio A, Mapagu C, Amant F, Friedlander M; PARAGON Investigators.

J Gynecol Oncol. 2019 Sep;30(5):e86. doi: 10.3802/jgo.2019.30.e86.

19.

Not everything is as it seems: a rare form of metastatic breast cancer.

Rocha M, Azevedo D, Teira A, Barbosa M.

Autops Case Rep. 2019 Jun 11;9(2):e2018085. doi: 10.4322/acr.2018.085. eCollection 2019 Apr-Jun.

Supplemental Content

Loading ...
Support Center